Trial reportInvestigational new drugs2013
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).
Trial report in Investigational new drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03023124 (Solitary Fibrous Tumor), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy.Targeted oncology · 2021Pooled it
- Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).Annals of oncology : official journal of the European Society for Medical Oncology · 2015Trial
- Systemic Therapy for Solitary Fibrous Tumor.Current treatment options in oncology · 2026Review
- Solitary fibrous tumor: an updated review.Journal of pathology and translational medicine · 2026Article
- A Rare Metastatic Fibrous Tumor: Review of Literature With a Case Report.JTO clinical and research reports · 2025Article
- Pediatric Spinal Solitary Fibrous Tumor: A Systematic Review of a Rare Condition.Children (Basel, Switzerland) · 2025Review
- Case report: A study on disease diagnosis and treatment outcome of a case of bilateral malignant solitary fibrous tumor of the kidneys.Frontiers in oncology · 2025Article
- MAPK-targeted therapies in non-gastrointestinal stromal tumor soft tissue sarcomas: current landscape and future directions.Frontiers in oncology · 2025Review
- Advances in the molecular biology of the solitary fibrous tumor and potential impact on clinical applications.Cancer metastasis reviews · 2024Review
- Review
- A giant breast malignant solitary fibrous tumor: A rare case report and brief review.Oncology letters · 2023Article
- Article
- Tyrosine kinase inhibitors in sarcoma treatment.Oncology letters · 2022Review
- Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond.Cancers · 2022Review
- Malignant solitary fibrous tumor in the central nervous system treated with surgery, radiotherapy and anlotinib: A case report.World journal of clinical cases · 2022Article
- Case report:Frontiers in oncology · 2022Article
- Review
- Radiation therapy strategies for skull-base malignancies.Journal of neuro-oncology · 2020Review
- Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review.Nagoya journal of medical science · 2020Article
- Treatment options in unresectable soft tissue and bone sarcoma of the extremities and pelvis - a systematic literature review.EFORT open reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant solitary fibrous tumors are rare soft-tissue sarcomas. They are considered as low-grade malignancies, but may display metastatic potential in 20% of the cases. In case of metastatic or locally advanced, unresectable disease, standard treatments, like anthracycline-based regimens, are poorly effective. Previous studies suggested that antiangiogenic drugs, such as sorafenib, could be efficient to treat vascular sarcomas and solitary fibrous tumors. Five patients with progressive SFT were included in this phase 2 study, and treated with sorafenib at a dose of 800 mg daily. Two patients out of the five achieved a 9 months disease control with sorafenib, while their disease had progressed within the month preceding their inclusion. Consequently, our data suggest a potential efficacy of sorafenib in SFT, Further investigation is needed to confirm these data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.